eXmoor

eXmoor Pharma is the only integrated cell and gene therapy (CGT) contract development and manufacturing organisation (CDMO) that embeds over 20 years of consultancy expertise across every stage of the CMC journey — from early-phase strategy through process development, GMP manufacturing, and commercialisation. Founded in 2004 and based in Bristol, UK, eXmoor specialised in the CGT sector from 2007 and has since supported 190+ clients worldwide across viral vectors, autologous and allogeneic cell therapies, and RNA technologies. The company operates a state-of-the-art Cell & Gene Therapy Centre spanning 65,000 sq ft with four independent Grade C GMP clean rooms, including a dedicated formulation and fill finish suite, and capacity for 2 x 200L bioreactor scale or five autologous cell therapy stations. With a 70% repeat business rate and a team of over 80 experts spanning process development, GMP manufacturing, facility design, and consulting, eXmoor provides end-to-end support from pre-clinical feasibility through commercial readiness. The company operates as a 100% fossil fuel-free facility and serves clients including Quell Therapeutics, King's College London, Cancer Research UK, New Zealand Blood Service, and the Cell and Gene Therapy Catapult.